Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

The notion of what qualifies as vascular dementia has varied greatly since the first mention
of dementia after apoplexy in ancient literature. Current insight points towards a …

Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …

Although white matter hyperintensities have traditionally been viewed as a marker of
vascular disease, recent pathology studies have found an association between white matter …

Introduction: Plasma glial fibrillary acidic protein (GFAP) may be associated with amyloid
burden, neurodegeneration, and stroke but its specificity for Alzheimer's disease (AD) in the …

Background and Objectives Treatment options for Alzheimer disease (AD) are limited and
have focused mainly on symptomatic therapy and improving quality of life. Recently …

Objective Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of
amyloid β (Aβ) in the walls of cortical vessels and the accrual of microbleeds and …

Cerebral microbleeds (CMBs) are a disorder of cerebral microvessels that are characterized
as small (< 10 mm), hypointense, round or ovoid lesions seen on T2*-weighted gradient …

Objective To report population age-specific prevalence of core cerebrovascular disease
lesions (infarctions, cerebral microbleeds, and white-matter hyperintensities detected with …

Background The development of cerebrospinal fluid and blood-based biomarkers for
Alzheimer disease (AD) and related disorders is rapidly progressing. Such biomarkers may …